Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ⅲ Study to Evaluate Efficacy and Safety of Lobaplatin and Carboplatin as Neoadjuvant Therapy in Participants With HER-2 Positive Breast Cancer.

NCT07093931 is registered in ClinicalTrials.gov with Shandong Cancer Hospital and Institute as lead sponsor.

NCT NCT07093931
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07093931 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ⅲ Study to Evaluate Efficacy and Safety of Lobaplatin and Carboplatin as Neoadjuvant Therapy in Participants With HER-2 Positive Breast Cancer.
Lead sponsor
Shandong Cancer Hospital and Institute
Phase
Phase 4
Overall status
Not yet recruiting
Start date
August 1, 2025
Completion date
August 1, 2030
Enrollment
468 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer